Advantages and Risks of Psychopharmacotherapy
Authors:
- L CandeliseLCL Candelise
- P FaglioniPFP Faglioni
- H SpinnlerHSH Spinnler
- L A VignoloLVL A Vignolo
- 29 November 1973
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 289 (22) , 1201-1202
Abstract
To the Editor: I am amused at the overemphasis recently placed on the risks of antipsychotic drug therapy.1 , 2 Risks including permanent and incurable tardive dyskinesia are in some cases quite trivial as compared to the devastating effects of psychotic behavior.The amount of human suffering attributable to schizophrenia, mania and other psychoses can truly be appreciated only if one takes a detailed conducted tour of the psychotic patient's life.It is because of the morbidity of these illnesses, and the waste of human talent and productivity as a direct result thereof, that we must not lose sight of the benefits . . .Keywords
This publication has 8 references indexed in Scilit:
- Risks vs. Benefits of Antipsychotic DrugsNew England Journal of Medicine, 1973
- Neurologic Syndromes Associated with Antipsychotic-Drug UseNew England Journal of Medicine, 1973
- Persistent DyskinesiaThe British Journal of Psychiatry, 1973
- The long-term effect of perphenazine enanthate on the rat brain. Some metabolic and anatomical observationsPsychopharmacology, 1973
- Persistence of Extra-pyramidal Disorders and Psychiatric Relapse after Withdrawal of Long-Term Phenothiazine TherapyThe British Journal of Psychiatry, 1972
- Very High Dosage Fluphenazine for Nonchronic Treatment-Refractory PatientsArchives of General Psychiatry, 1971
- NEUROPATHOLOGICAL INVESTIGATION OF 28 BRAINS FROM PATIENTS WITH DYSKINESIAActa Psychiatrica Scandinavica, 1970
- Dyskinesia and NeurolepticsArchives of General Psychiatry, 1968